Expert group calls for more commitment to African clinical trial coordination

29 July 2007

An expert group, asked by the European Commission to review the only research program so far established to combine European Union and national funds, has said that any future programs need a much stronger up-front commitment from EU member states.

The group, chaired by former Member of the European Parliament Wim Van Velzen, was asked to look at the European and Developing Countries Clinical Trials Partnership (EDCTP), a common research program designed to pool resources from the EU research budget and national research programs for clinical trials in the area of HIV/AIDS, malaria and tuberculosis, and to make recommendations for improving EDCTP and for future projects. A number of recommendations are addressed to the management of the EDCTP program and its "owners" among the member states. Further recommendations are addressed to the Commission, to be borne in mind when future such "Article 169" proposals for the coordination of national and European research programs are prepared.

Political commitment required

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight